Novo Nordisk is preparing for a surge of generic semaglutide drugs in India. The company's India head stated they will monitor rivals' pricing and market strategies closely. With many companies launching cheaper versions, Novo Nordisk plans to evaluate the market before reacting. This move comes as the blockbuster diabetes and weight-loss drug's patent expires.